Hinge Health (HNGE) Earnings Date & Reports

Key Takeaways

• Hinge Health is scheduled to report results for its third quarter of 2026 (the period ended September 30, 2026) after the market close on Monday, November 2, 2026.
• Wall Street consensus points to roughly $225 million in quarterly revenue and non-GAAP earnings of about $0.58 per share.
• The company guided third-quarter revenue to $223 million to $225 million, implying roughly 45% year-over-year growth at the midpoint.
• In its last report, Hinge Health posted $212.8 million in revenue (up 53% year over year) and $0.59 in non-GAAP earnings per share.
• Management raised full-year 2026 revenue guidance to $856 million to $860 million, reflecting about 46% growth at the midpoint.
• The stock trades near its 52-week high, with analysts carrying a consensus Buy rating and an average price target near $113.
• For more detail on the company, visit Tickeron's pages for Major News, Today's Price Move, Price Targets, and Forecast.
• Explore Trending AI Robots to see AI-driven trading strategies currently drawing investor attention.

Earnings Context and Why It Matters

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) care, delivering software and AI-powered programs to self-insured employers and health plans. The company has become a standout in the digital-health sector by pairing rapid revenue growth with a sharp turn to profitability. Coming into this report, Hinge Health has consistently beaten or met its own guidance while expanding operating margins and generating meaningful free cash flow. For investors, the third-quarter update serves as a check on whether that momentum can continue through the second half of 2026, especially with the company's pending acquisition of Cylinder Health and its expansion beyond musculoskeletal care into areas such as migraine treatment.

Earnings Expectations

For the third quarter of 2026, analysts expect revenue of approximately $224.8 million, up roughly 46% from the $154.2 million reported in the same quarter a year earlier. The consensus non-GAAP earnings per share estimate sits near $0.58. Management's own guidance calls for revenue of $223 million to $225 million, implying about 45% year-over-year growth at the midpoint, while full-year 2026 guidance was raised to $856 million to $860 million.

The company enters this print with a strong track record. In the second quarter, revenue of $212.8 million grew 53% year over year and beat guidance, while non-GAAP operating income rose sharply and free cash flow reached $99.6 million. Notably, second-quarter non-GAAP EPS of $0.59 came in slightly below the roughly $0.62 consensus, a reminder that even a strong top-line beat can fall short on profitability metrics. Investors will be watching whether Hinge Health can again exceed its revenue guide and whether operating margins and cash flow keep improving alongside the acquisition and multi-product expansion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking earnings-driven movers like Hinge Health, the AI Screener offers a practical way to surface comparable names and potential setups across the healthcare technology space.

Market Reaction and Investor Sentiment

Sentiment heading into the report is broadly optimistic. Hinge Health shares have climbed sharply since the company's May 2025 initial public offering and currently trade near the upper end of their 52-week range, with a market value of roughly $9 billion. Analyst actions have been positive in recent weeks, with several firms raising price targets and maintaining Buy or Overweight ratings ahead of the print.

That enthusiasm also raises the bar. With the stock trading at a premium valuation, the market has largely priced in continued strong execution, meaning a merely in-line quarter may not be enough to satisfy investors. Key risk factors include the pace of revenue deceleration through the second half, the timing and integration of the Cylinder Health acquisition, and any signs of margin or cash-flow pressure as the company scales new product lines beyond its core musculoskeletal offering.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, the central question is whether Hinge Health can sustain high growth while defending its expanding profitability. The company's guided path implies a gradual deceleration from the 53% growth posted in the second quarter, which management has framed as a natural comparison effect against a stronger second half of 2025. Investors will be watching whether the company raises its full-year outlook once again, as it has done multiple times in the past year.

Several factors deserve close attention. First, the integration of Cylinder Health, a virtual-first digestive-care provider acquired for $105 million in cash, adds strategic reach but is expected to contribute only modest revenue in 2026. Second, the rollout of newer offerings such as the migraine program could shape the growth narrative into 2027. Third, operating leverage and free cash flow remain key proof points for the profitability story that has set Hinge Health apart from less profitable digital-health peers.

Finally, valuation will remain a recurring theme. With shares trading at a premium multiple relative to sales, the stock's reaction will likely hinge on whether management can keep delivering beats and upward revisions rather than simply meeting expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations